Investigational drug · Phase 2
BGC101
Also called: autologous EnEPC preparation
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BGC101"
First trial start
2016
Jun 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BGC101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Limb-Threatening Ischemia
- Peripheral Arterial Disease
- Peripheral Vascular Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "BGC101" as an intervention, largest first.
- BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)Active, not recruiting
BioGenCell Ltd.Biogen (BIIB)
NCT02805023 · 40 participants (planned) · Start Jun 2016 · Primary completion Jul 2017
Drug: BGC101 (autologous EnEPC preparation); Control medium · For: Chronic Limb-Threatening Ischemia; Peripheral Arterial Disease; Peripheral Vascular Disease
Sites: San Francisco, California; New Haven, Connecticut; Baltimore, Maryland · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A novel potential therapy for vascular diseases: blood-derived stem/progenitor cells specifically activated by dendritic cells.
Porat Y, Assa-Kunik E, Belkin M, et al. · Diabetes Metab Res Rev 2014
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Biogen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.